Status:
RECRUITING
REGistry of Long-term AnTithrombotic TherApy-2
Lead Sponsor:
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with atrial fibrillation
Detailed Description
The register is a Russian prospective single-center observational study of patients who have indications for long-term antithrombotic therapy in connection with atrial fibrillation
Eligibility Criteria
Inclusion
- Documented atrial fibrillation with CHA2DS2VASC \> 1
Exclusion
- Subjects who are unwilling or unable to provide informed consent. ACS within 12 months before inclusion Severe CHF (NYHA IV) Stroke within 6 months before inclusion Severe liver or muscle disease Severe kidney disease / renal failure with creatinine \> 3 mg/dl Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention
Key Trial Info
Start Date :
January 15 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04347187
Start Date
January 15 2015
End Date
December 31 2026
Last Update
March 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Moscow, Russia, 121552